Compare RBLX & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBLX | ZTS |
|---|---|---|
| Founded | 2006 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.1B | 53.9B |
| IPO Year | 2021 | 2013 |
| Metric | RBLX | ZTS |
|---|---|---|
| Price | $82.16 | $122.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 11 |
| Target Price | $141.36 | ★ $174.60 |
| AVG Volume (30 Days) | ★ 7.7M | 6.5M |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | N/A | ★ 11.64 |
| EPS | N/A | ★ 5.94 |
| Revenue | $4,463,713,000.00 | ★ $9,397,000,000.00 |
| Revenue This Year | $87.95 | $3.11 |
| Revenue Next Year | $21.71 | $5.14 |
| P/E Ratio | ★ N/A | $20.59 |
| Revenue Growth | ★ 32.70 | 2.68 |
| 52 Week Low | $50.10 | $115.25 |
| 52 Week High | $150.59 | $177.40 |
| Indicator | RBLX | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 28.23 | 47.49 |
| Support Level | $81.25 | $122.00 |
| Resistance Level | $89.19 | $125.53 |
| Average True Range (ATR) | 3.30 | 3.00 |
| MACD | -0.37 | 0.91 |
| Stochastic Oscillator | 5.68 | 66.06 |
Roblox operates a free-to-play online video game platform with about 150 million daily active users. This platform has spawned a virtual universe and a Roblox economy based on the Robux currency. The platform houses millions of games from a wide range of creators—spanning from young gamers themselves to professional development studios. Roblox offers creators the tools, publishing abilities, and platform for their games, enabling anyone to create a game. Creators earn money when gamers make optional in-game purchases within their games and by offering space for real-world advertising, and Roblox earns revenue primarily by taking a cut of these earnings.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.